DXCM vs TECH · P/E 63, rev $4.03B vs P/E 65, rev $1.22B
DexCom Inc (DXCM) versus Bio-Techne Corp (TECH) — a side-by-side from cached financials, not a winner call.
DexCom Inc (DXCM) is a medical devices company listed on US.
Bio-Techne Corp (TECH) is a biotechnology company listed on US.
Latest reported DXCM revenue for 2024-12-31 was $4.03B. Net income was $576.2M. Revenue was up 11.3% from 2023-12-31 to 2024-12-31. DXCM currently screens at market cap $32.84B and trailing P/E 62.5.
Latest reported TECH revenue for 2025-06-30 was $1.22B. Net income was $73.4M. Revenue was up 5.2% from 2024-06-30 to 2025-06-30. TECH currently screens at market cap $8.49B and trailing P/E 65.2.
DXCM currently screens at market cap $32.84B and trailing P/E 62.5. TECH currently screens at market cap $8.49B and trailing P/E 65.2.
Not investment advice. Open the DXCM and TECH stock pages for the full models.
Not investment advice.